Should AstraZeneca plc (ADR) (AZN) and Bristol Myers Squibb Co. (BMY) Get Married?

Page 1 of 2

It’s been quite a while since we had a big wedding in the pharma world. Sure, there have been plenty of small acquisitions, but no really big merger has happened over the past few years. One potential pharmaceutical friendship often rumored to possibly develop into something more serious involves AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY). Would a marriage between these two companies be a match made in heaven? Let’s take a look.

AstraZeneca plc (ADR) (NYSE:AZN)

Going to the chapel
If AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY). were people, we could easily spot one good reason for them to get married: They have a lot in common. Just look at the two companies’ portfolios.

Both organizations boast a strong presence in the cardiovascular market. AstraZeneca’s Crestor stands as a leading cholesterol drug with sales over $6.2 billion in 2012. Bristol Myers Squibb Co. (NYSE:BMY) blood thinner, Plavix, brought in $2.5 billion in sales.

Neuroscience stands out as another strong area for both companies. AstraZeneca plc (ADR) (NYSE:AZN) made $2.8 billion last year from Seroquel IR and Seroquel XR schizophrenia and bipolar disorder drugs. Bristol Myers Squibb Co. (NYSE:BMY) Abilify treats the same indications and likewise brought in around $2.8 billion in 2012 sales.

Of course, it’s also important that married couples have differences that complement each other. That’s true for our two potential lovebirds. While sales for AstraZeneca’s Nexium and Losec/Prilosec are slowing down, they’re still contributing significantly. Bristol Myers Squibb Co. (NYSE:BMY) doesn’t count any gastrointestinal products among its leading drugs.

However, Bristol-Myers Squibb can claim success in at least one area that isn’t strong for AstraZeneca plc (ADR) (NYSE:AZN) – treatment of HIV and AIDS. Combined sales for the company’s Reyataz and Sustiva HIV drugs topped $3 billion last year.

Another argument in favor of AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) getting hitched is that they have children together. Well, sort of. Bristol-Myers Squibb bought Amylin Pharmaceuticals last year for around $7 billion. Nearly half of that amount was financed by AstraZeneca plc (ADR) (NYSE:AZN) . Both companies share in the profits from Amylin’s diabetes drugs, including Bydureon and Byetta.

This wasn’t the first time AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) collaborated in the diabetes arena. The two companies previously developed Onglyza together. However, sales for Onglyza weren’t as strong as hoped for as Merck & Co., Inc. (NYSE:MRK)‘s Januvia won greater market share. They also partnered on Forxiga, which has encountered its own difficulties.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!